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Background: To analyze the expression at basal level of inflammation-related cytokines and chemokines and the
activation status of the NF-κB pathway, together with the proliferation and apoptosis indexes in two widely used
in vitro tumor models, the androgen-dependent human Prostate Cancer (PC) cell line LNCaP and the androgen-
independent PC3 , and in primary cultures of human PC cells. To assess in these models and primary cultures, the
effects of Serenoa repens (LSESr, PermixonW) on proliferation/apoptosis ratio, inflammation-related genes expression
and NF-κB pathway activation.
Methods: The expression of IL-6, CCL-5, CCL-2, COX-1, COX-2, iNOS inflammation-related genes has been evaluated at
the mRNA level in two in vitro human PC models (LNCaP and PC3 cell lines) and in 40 independent human prostatic
primary cultures obtained from PC patients undergoing radical prostatectomy. Tissue fragments were collected from
both PC lesions and normal hyperplastic tissue counterparts for each case. All cultures were treated with two different
amounts of PermixonW (44 and 88 μg/ml) for different time points (16, 24, 48 and 72 hours), depending on the cell
type and the assay; the expression of inflammation-related genes, cell growth (proliferation/apoptosis ratio) and NF-κB
activation has been analyzed in treated and untreated cells by means of semi-quantitative RNA-PCR, cell proliferation
and immunofluorescence respectively.
Results: We detected a significant reduction (p <0.001) in PC and normal cells proliferation due to Permixon W
treatment. This result was related to an increase of the apoptotic activity showed by an increase in the number of
anti-caspase-3 fluorescent cells. Almost all the inflammation-related genes (IL-6, CCL-5, CCL-2, COX-2 and iNOS)
were expressed at the basal level in in vitro cultured cells and primary cultures and down-regulated by PermixonW
treatment. This treatment interfered with NF-kB activation, detecting by the translocation of more than 30% of
NF-κB p65 subunit to the nucleus.
Conclusions: The present study confirms the expression of inflammatory pattern in PC. We showed the effect of
PermixonW on down-regulation of inflammatory-related genes in cell lines and in primary cultures. The inhibitory effect
of PermixonW on cell growth could be partly associated to the down-regulation of inflammatory-related genes and to
the activation of NF-κB pathway in prostate tissue.
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Table 1 Clinical characteristics of the 40 cases included
for the analysis on primary cultures (number of cases and
mean ± SD)
Number of cases 40
Age (years) 65.0 ± 3.3
Prostate volume (ml) 43.4 ± 6.8
PSA (ng/ml) 6.8 ± 2.4
Pathological stage 36 pT2
4 pT3a
Pathological Gleason score 27 ≤ 7 (3 + 4)
13 ≥ 7 (4 + 3)
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Evidences in literature suggest that prostatic inflammation
is involved in the pathogenesis and progression of pros-
tatic diseases, such as benign prostatic hyperplasia (BPH)
and prostate cancer (PC). Epidemiologic, histopathologic
and molecular pathologic studies support the association
between prostate inflammation and prostate diseases,
suggesting a possible mechanism of action [1-7].
The lipidosterolic extract of the fruits of the American
dwarf palm tree Serenoa repens (LSESr) (Permixon) is
probably the most studied phytotherapeutic drug, widely
used for lower urinary tract symptoms (LUTS) treatment.
A large number of pharmacodynamic effects, observed
in vitro and in vivo, suggest multiple mechanisms of ac-
tion on the human prostatic tissue, such as the anti-
androgen effect [8,9], and the interference with mediators
of inflammation [10-12] and with proliferative-apoptosis
pathways [13]. Different studies [10-12], which tested the
pharmacological properties of this drug on the inflamma-
tory status of the prostatic tissue, concluded that the
LSESr might have a potential anti-inflammatory effect.
The aim of our study is to analyze and to compare the
expression of the inflammatory pathways in human PC cell
lines, such as androgen-dependent LNCap and androgen-
independent PC3 cell lines and in primary cultures of
human prostate adenocarcinoma cells. On these different
settings, we also evaluated the effect of LSESr (Permixon)
on different inflammatory factors, analyzing whether its




LNCaP and PC3 cell lines were obtained from Interlab
Cell Line Collection (ICLC) (Istituto Nazionale per la
Ricerca sul Cancro, Genoa, Italy).
Human cancer epithelial cell line PC3 was grown in
DMEM (Euroclone, Life Science Division, GB, Pero, Italy)
supplemented with 10% fetal bovine serum (Euroclone)
and LNCaP in RPMI 1640 (Euroclone). Cells were
maintained in a tissue culture incubator at 37°C, 5% CO2.
Cells were treated with LSESr (44–88 μg/ml) at different
incubation times (24, 48 and 72 hours) and after RNA ex-
traction, RT-PCR assay was performed at the same inter-
vals of time.
Ex vivo primary cultures
This experimental study was conducted after approval of
the protocol from our Institutional Board Committee and
informed consent was obtained from all patients. Exclusion
criteria for the study were: previous hormonal, surgical
or radiation therapies for prostate diseases; acute inflam-
matory diseases. Table 1 summarizes the characteristics
of donors.We derived human epithelial cultures from tissue
explanted from 40 patients undergoing radical prostatec-
tomy for prostate adenocarcinoma. At surgery, after pros-
tate removal, tissue samples were put on ice in Falcon
tube containing 5 ml of minimum essential medium
(Euroclone) and transferred in laboratory where they were
immediately processed. From these cases (40 cases), we
processed tissue fragments either from PC nodules (named
Tumor “T”) or from normal tissue (named control “Ct”).
The histological status of the tissue was checked by an in-
dependent pathologist.
In brief, the fresh tumor and normal tissue specimens
were cut in small pieces and digested with trypsin under
stirring 2 hours at 37°C. After filtration through 70 μm
nylon cell strainer, epithelial cells were grown in PrEGM
(Prostate Epithelial Growth Medium), containing the
standard prostatic epithelial cell media additives (PrEGM
Bullet Kit), including bovine pituitary extract, insulin,
transferrin, epidermal growth factor, hydrocortisone, retin-
oic acid, epinephrine, and tri-iodothyronine, from Lonza.
After two weeks, when the different cells showed an
exponential growth rate, they were treated with LSESr
(PermixonW, Pierre Fabre Médicament, Castres, France).
Preparation of LSESr (PermixonW) and stimulation
settings
LSESr (Permixon) was obtained as a hexane extract from
Pierre Fabre Medicament (Castres, France). The hexane
was evaporated to leave the solid extract. The solid was
dissolved in 10 ml of ethanol, to give a concentration of
10 mg/ml. This stock solution was further diluted in ap-
propriate media to provide a working solution of 1 mg/ml.
Cell counting
To determine the cell counting, LNCaP, PC3 and primary
prostate cells were plated and subconfluent cells were
treated with LSESr (Permixon) at a concentration of 44
and 88 μg/ml at different incubation times (6, 9, 24, 48 and
72 hours). After treatment cells were trypsinized, washed
in-Phosphate buffered saline (PBS) and after centrifugation
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aliquot of each cell line was diluted 1:1 with 0.4% of
trypsan blue. Cells were then loaded into a Neubauer
chamber and living cells (unstained) were counted under a
light microscope. Each assay was carried out in triplicate
and the mean value was determined.
Cyototoxic assay
LNCaP and PC3 cells were seeded in triplicate in 96-well
plates at 5.0 × 104 cells per well. After 24 hours, Serenoa
Repens (44 μg/ml) was added in a red phenol free DMEM
medium for 48 and 72 hours, then cells were incubated
with 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazo-
lium-5-carboxanilide inner salt (XTT; Cell Proliferation kit
Sigma-Aldrich) following the manufacturer’s instruction.
Absorbance was measured at 450 nm using a microplate
reader (Labsystem Multiskan MS), the absorbance at
690 nm was subtracted from the 450 nm value and cyto-
toxicity was calculated by comparing absorbance of
treated cultures with the absorbance of the untreated cul-
tures at 48 and 72 hours.
Caspase detection
In PC3 cell line and in primary cultures, anti-activated
Caspase-3 antibody (Cell Signalling Technology) was
used to carry out immunofluorescence assay and to in-
vestigate apoptosis induced in different cells by LSESr
(Permixon). Cells were grown on Labteck chamber slides
(Nunc, Naperville, Illinois, USA) for 24 hours, then
treated with LSESr (Permixon) 44 μg/ml for 16 hours
and analysed with immunocytochemistry using anti-
cleaved caspase-3 and rhodamine indirect labelling. Cells
treated and controls were fixed and permeabilized in
methanol at −20°C for 10 min, rinsed in PBS, incubated
for 1 hour at room temperature with TRITC-conjugated
anti-rabbit IgG (1:500, Molecular Probes) and then ex-
amined under fluorescence microscope (Olympus BX-52).
Reverse transcriptase polymerase chain reaction (RT-PCR)
assay
Total RNA from LNCaP, PC3 and human prostate primary
cells were extracted using Trizol reagent (Invitrogene,
Carlsband, CA) according to the manufacturer’s in-
structions. High quality RNA preparations have been
re-suspended in nuclease-free water and subjected to
semi-quantitative polymerase chain reaction (RT-PCR).
Moloney murine leukemia virus (M-MLV) reverse tran-
scriptase (Biolab) was used to convert 1 μg of total RNA
into cDNA at 42°C. 5 μg of each cDNA was then
subjected to RT-PCR in a buffer containing 25 pmol of
upstream and downstream and 1.25U of Platinum Taq
polymerase (Euroclone). The amount of amplified prod-
ucts, expressed in arbitrary optical density units, was nor-
malized with glyceraldehyde-3-phosphate dehydrogenase(GADPH) as housekeeping gene. The sequences of human
gene-specific primers and the conditions of amplification
as well as the amplified products size are listed in Table 1,
with order of forward and reverse. The amplification reac-
tion was carried out in PCR-expressed cyclers (TECHNE
USI Instrument). The resulting PCR products were se-
parated in 2% agarose gel and visualized with ethidium
bromide. The primer sequences, amplification sizes and
amplification conditions for each gene are listed in Table 2.
Immunofluorescence
The protocol was performed only in LNCaP and PC3
culture cell lines. Cells were grown on Labteck chamber
slides (Nunc, Naperville, Illinois, USA) and treated with
LSESr (Permixon). After treatment, cells were washed
with phosphate-buffered saline (PBS) and fixed with ab-
solute methanol for 5 minutes at −20°C. Cells were then
incubated for 1 hour with rabbit polyclonal antibody to
p65 (Santa Cruz Biotechnology), rinsed three times with
PBS and then incubated with fluorescein isothiocyanate-
conjugated anti-rabbit IgG (Sigma, Milano, Italy) for 1 -
hour. Cells were then rinsed three times with PBS and
mounted with Prolong anti-fade reagent, and the fluor-
escence was analyzed by an Olympus BX52 (Hamburg,
Germany) fluorescence microscope. The images were ac-
quired and elaborated with IAS 2000 software (Delta
Sistemi, Rome, Italy).
Statistical analysis
Statistical significance was determined using a one tailed
Student’s t test (PRISM statistical analysis software) and
data were expressed as means ± standard deviation (SD)
of independent samplings from different experiments. A
cut-off of p < 0.05 was used to demonstrate significance.
Results
Cell counting, citotoxicity assay and apoptosis activation
To evaluate the inhibitory effect of PermixonW on in vitro
cell growth, we analyzed cell viability by direct cell
counting. As shown in Figure 1, in both LNCaP and PC3
tumor cell lines, PermixonW treatment significantly reduced
cell growth at all time points (24, 48 and 72 hours after
stimulation) when compared to untreated cells (p < 0.05).
Reported effects are not dose-dependent as differences
achieved with the two doses of PermixonW (i.e. 44 and
88 μg/ml) were not statistically significant (p > 0.05). A
similar result was observed also using XTT (Figure 2).
The cells of 90% out of 40 independent human pros-
tate primary specimens were grown in ex-vivo cultures.
Human samples were screened by means of RT-PCR for
the expression of CD45 and CK5/CK8 markers to assess
the epithelial origin of cultured cells; only CD45 nega-
tive/CK5-CK8 positive cultures have been used for
Table 2 Primers sequences and amplification conditions
Gene Sequences 5’-3’ Cicli Annealing (temp C) Size (bp)
GADPH ACATGTTCCAATATGATTCC 30 60°×30” 180
TGGACTCCACGACGTACTCAG
Il-6 CCTCCAGAACAGTTTGAGA 30 56°×1’ 280
CCTTAAAGCTGCGCAGAATG
CCL-5 CTCGCTGTCATCCTCATTGCT 30 62°×30” 394
TACTCCCGAACCCATTTCTTCTC
CCL-2 ATG AAA GTC TCT GCC GCC CTT CTG T 36 60°×30” 286
AGT CTT CGG AGT TTG GGT TTG CTT G
COX-1 TGC CCA GCT CCT GGC CCG CCG CTT 30 60°×1’ 304
GTG CAT CAA CAC AGG CGC CTC TTC
COX-2 TTC AAA TGA GAT TGT GGG AAA AT 30 60°×1’ 305
AGA TCA TCT CTG CCT GAG TAT CTT
iNOS TGG TGC TGT ATT TCC TTA CGA GGC GAA GAA GG 35 60°×45” 259
GGT GCT TCT TGT TAG GAG GTC AAG TAA AGG GC
The PCR amplification programme was as follows: an initial period of 5 min at 95°C, followed by a variable number of cycles of denaturation at 95°C for 30 sec,
annealing (see Table 1) and finally 30 sec of extension at 72°C. The programme was terminated with a period of 10 min at 72°C. To be within the exponential
phase of the semiquantitative PCR reaction, the appropriate number of cycles was newly established for every set of samples. PCR products were separated by gel
electrophoresis on 15% agarose gels and visualized by ethidium bromide staining. All gels were scanned and the normalizedintensities of all reverse transcription
(RT)-PCR products were determined by the BioRad gel documentation system (BioRad, Hercules, CA, U.S.A.). Mean ± SEM intensities were calculated for all
RT-PCR experiments.
Figure 1 Cell counting by trypsan blue in LNCaP and PC3 cell lines. Results are presented at 24, 48 and 72 hours of incubation, either in
untreated or in PermixonW treated (44 and 88 μg/ml) conditions. Cells were seeded at different concentration, lower for longer incubation time in
order to avoid overgrowth. The same amount of cells was used to start each incubation time, control and treated cells. a) LNCaP. b) PC3. * = p < 0.05.
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Figure 2 Cytitoxicity assay in LNCaP cell and PC3 lines. Results are
presented at 48 and 72 hours of incubation, either in untreated or in
Permixon treated (44 and 88 μg/ml) conditions. The graphic shows the
reduction of cell growth according to the absorbance of treated and
untreated cultures (XTT Cell Proliferation kit Sigma-Aldrich). Figure 3 Cell counting in human primary cells. Results are
presented at 16 hours of incubation either in untreated or in
PermixonW treated (44 μg/ml) conditions. This result represents the
total number of cells harvested after 16 hours of incubation. The
same amount of cell was seeded for each control and treated cells.
Tumor cells = prostate adenocarcinoma primary cultures; Control
cells = normal cell primary culture. * = p < 0.05.
Figure 4 Detection of caspase-3 in apoptotic cells.
Immunocytochemistry (immunofluorescence) with anti-cleaved
caspase3 by rhodamine indirect labelling. The upper panels are PC3
untreated (a) and treated (b) with LSESr for 16 hours. The lower
panels are primary cells line untreated (c) and treated (d) with
PermixonW for 16 hours. Untreated cells show no labelling with the
anti-cleaved caspase-3 antibody and TRITC anti IgG. LSERSr treated
cells show (arrows) labelling with anti-cleaved caspase-3.
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be completely excluded (36).
Cultured human prostate primary cells were in vitro ex-
panded and assayed for cell growth. A relatively slow cell
proliferation rate has been observed in all human samples
and none of the ex-vivo cultures has been immortalized so
far. Furthermore, cell growth of human primary cells was
more promptly inhibited by PermixonW compared to
LNCaP and PC3 cell lines. Consequently, on human pri-
mary samples we reported the effect of only one dose of
PermixonW (44 μg/ml) and cells have been collected after
16 hours of stimulation. As shown in Figure 3, both in the
tumoral and normal primary counterparts, PermixonW re-
duced significantly cell growth when compared to un-
treated controls (p < 0.05).
To determine whether PermixonW induced inhibition of
cell growth was due to an increase in apoptosis index, the
caspase-3 activation has been evaluated by means of im-
munofluorescence. This assay has been performed on PC3
cell line and human primary cultures. Results showed a
significant (p > 0.05) increase in the number of detached
cells (mainly in human primary samples) and of anti-
caspase-3 fluorescent cells (Figure 4).
Inflammation-related genes expression
To evaluate in all our experimental samples the expression
pattern of inflammation-related genes in untreated (in vitro
basal level) and PermixonW treated conditions, we
performed expression analysis at RNA level of the follow-
ing genes: IL-6, CCL-5 (RANTES), CCL-2, COX-1, COX-
2 and iNOS.
IL-6
In untreated conditions we observed elevated expression
of IL-6 in PC3 cells, while no expression was detected inLNCaP cells. In untreated in vitro cultured human pri-
mary cells we detected a high expression of IL-6, al-
though lower if compared to the expression in PC3 cells.
In both PC3 cells and human primary cells, PermixonW
treatment induced a down-regulation of IL-6 gene,
(mainly at 24 and 72 hours in PC3 cells and even after
8 hours in human primary cells), Figure 5.
Figure 5 GADPH, IL-6, CCL-5 (RANTES), CCL-2, COX-1, COX-2 and iNOS RT-PCR products separated on a 2% agarose gel followed by
ethidium bromide staining in PC3, LNCaP and primary cells lines. In PC3 (panel 1) and LNCaP (panel 2) analysis was performed at 8, 24 and
72 hours of incubation whereas in primary cell lines (panel 3) at 16 hours of interval. Here we report results obtained from one prostatectomy,
representative of 40 independent experiments. The experiment was performed in untreated and LSESr treated (44 μg/ml and 88 μg/ml in PC3
and LNCaP and only 44 μg/ml in primary cultures) conditions. UN = untreated; LS = LSESr treated; T = primary cells culture derived from PC
nodules; Ct = primary cells culture derived from normal prostate tissue surrounding the tumor.
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In untreated conditions we observed high expression of
CCL-5 gene in PC3 cells. As for IL-6 gene, also for CCL-5,
we could not detect expression in LNCaP cells. PermixonW
treatment, at all time points analyzed (8, 24 and 72 hours)
reduced CCL-5 expression in PC3 cells. The expression of
CCL-5 in untreated human primary cells was higher com-
pared to PC3 cells and even after 8 hours of PermixonW
treatment, we observed a down-regulation of this gene in
primary cells, Figure 5.
CCL-2
We observed high expression of CCL-2 in both PC3 and
LNCaP untreated cell lines and reported gene down-
regulation after 8, 24 and 72 hours of in vitro PermixonW
treatment. A similar high level of expression has been ob-
served in human primary cultures and similar trend ofdown-regulation after 16 hours of PermixonW treatment,
Figure 5.
Cyclo-oxygenase 1 and 2 (COX-1 and COX-2)
We observed elevated levels of COX-1 expression in PC3
untreated cells while no expression was detected in
LNCaP untreated cells. PermixonW treatment had signifi-
cant effect on the expression of COX-1 gene in treated
PC3 cells. Primary cell cultures, from both tumor and nor-
mal tissue specimens, showed high level of COX-1 expres-
sion, but on these samples PermixonW treatment had no
effects (Figure 5). On the other hand, COX-2 expression
was high in untreated PC3 cells and human primary cul-
tures, while no expression was detected in untreated
LNCaP cells. PermixonW treatment, at all time points
analysed (8, 16, 24 and 72 hours), did not show down-
modulation of COX-2 gene expression.
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Although high level of iNOS expression has been detected
in both PC3 and LNCaP cell lines, PermixonW treatment
had effect on gene down-modulation only in PC3 cells,
while no effect has been detected in LNCaP cells. In hu-
man primary cells, PermixonW reduced iNOS gene expres-
sion even after 16 hours of treatment, Figure 5.NF-κB pathway activation
Analysis of NF-κB activation has been performed only on
LNCaP and PC3 cell lines. In untreated conditions NF-κB
p65 subunit was detected only in the cytoplasm, while 24
and 48 hours after PermixonW treatment more than 30%
of NF-κB p65 subunit translocated to the nucleus, Figure 6.
Therefore LSESr treatment can also interfere with NF-kB
activation.Discussion
This study shows for first time that primary human PC
cells are influenced in growth and apoptosis pathways by
natural compounds such as LSESr (Permixon), which
down-regulates the inflammation pattern.
The use of primary prostatic tissue represent a good
model of study for these experiments compared to cells
in continue culture (LNCaP and PC3) because it reflects
a more realistic biological state of human prostate cells
[14,15]. It is considered that primary cells retain many
phenotypic characteristics of the original tissue, includ-
ing physiological functions and therefore they can be an
appropriate model also for drugs testing.
Doses of LSESr (Permixon) and incubation times were
sourced from the literature in PC cell lines, also if a large
variability exists [16-19]. Regarding the dose of LSESr
(Permixon), different studies suggested that 10 μg/ml
well represents the calculated plasma concentration in
patients receiving the recommended therapeutic dosage
[18]. Previous studies showed that in PC cell lines higherFigure 6 NF-κB detection. Immunofluorescence of p65 NF-κB in PC3 (a, b
is 100% detected in the cytoplasm of cells (arrows). After LSESr (44 μg/ml)
than 30% of NF-κB translocated at nuclear level (arrows).doses are needed to obtain significant results, which are
also influenced by a dose dependent effect [16-20].
The first result obtained in our study is that in every ex-
periment (LNCaP, PC3 and primary cultures) we detected
a significant reduction in PC cells counting caused by
LSESr (Permixon) treatment. Comparable results were also
observed in cells derived from normal prostate tissue. We
stopped the analysis at 16 hours and used only 44 μg/ml of
LSESr (Permixon) because the cells derived from primary
cultures showed a more inhibited growth when incubated
with LSESr (Permixon). These findings suggest that the
sensibility to LSESr (Permixon) depends on the cell line,
and the response is stronger in primary cultures.
Our results highlight that the inhibited growth ob-
served after treatment with LSESr (Permixon) is deter-
mined by the activation of a cellular mechanism related
to apoptosis. In the same condition, we also detected an
induction of the apoptotic pathway, under LSESr treat-
ment, caused by the caspase-3 activation [21,22].
However other studies detected apoptosis after Serenoa
repens treatment [17,23]; some authors demonstrated that
Permixon can effect prostate cancer cell growth without
inducing apoptosis [24]. Different results are possibly due
to: different preparation of the drug in various laboratories
can contain a different active amount of Serenoa repens or
same cell line after a long time in culture can get some dif-
ferent biological activity for mutation in its genotype [25].
The second result obtained from our study is that LSESr
(Pemixon) produces a down-regulation of most of the
inflammatory-related genes tested. We underline that this
study analysed also COX and iNOS genes expression and
we showed a down-regulation of both COX-1 and iNOS
induced by LSESr (Permixon) in PC3 cell line as in several
primary cell cultures.
In this study we had the possibility to evaluate in the
same experiment and in primary cultures the major
inflammatory-related genes, which might be responsible
for influencing PC disease. All these inflammatory-related, c) and LNCaP (d, e, f) cell lines. In untreated condition (a, d) NF-κB
treatment (b, e) = 24 hours and (c, f) = 48 hours of incubation more
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were down-regulated by LSESr (Permixon) in primary cul-
tures and in PC3 cell lines. However, in LNCap cell line,
only CCL-2 and iNOS genes were expressed. The lack of
expression for most of the inflammatory genes in LNCaP
line may be related to the different origin of these cells,
which are androgen-dependent and do not express IL-6
protein [26]. A quantitative analysis of inflammatory
markers and their modifications under treatment should
be very important and should be added at our experi-
ments; this represent a strong limit of this study and other
results are still necessary.
Finally, we analysed NF-kB gene expression by im-
munofluorescence. NF-kB is anchorated in the cytoplasm
in an inactive form by the association with a cell family
inhibitor of kappa B (IkB). Different signals can induce
IkB phpsphorilation and degradation by proteosomes, so
that NF-kB is translocated in the nucleus, where it can
induce the transcription of multiple genes. Such NF-kB
activation can induce either pathways that promote cell
survival or other pathways that promote cell death. The
different effects mediated by NF-kB depend on the acti-
vated signals and the type of tissue or cell line [27-31].
The antibody to NF-kB used in the present paper has
been previously utilized by other authors to asses NF-kB
activation by immunofluorescent staining of NF-kB nu-
clear translocation [32,33].
We showed that in LNCaP and PC3 line, LSESr
(Permixon) induces activation of NF-kB through its trans-
location in the cell nucleus. A down-regulation of the differ-
ent inflammatory-related genes and a significant reduction
in PC cell counting related to an apoptotic process was
found at the same time of incubation and concentration
of LSESr (Permixon) in which NF-kB was activated.
Our findings support the hypothesis that LSESr
(Permixon) might have an inhibitory effect on the expres-
sion of inflammation related genes. We can suppose that
LSESr (Permixon) can stimulate NF-kB pathway leading to
a pro-death response. However, we can expect that LSESr
(Permixon) acts via different mechanisms to inhibit cell
proliferation in LNCaP cell line. Nevertheless, the correl-
ation of NF-kB with proliferation and apoptotic responses
need further investigation caused by different androgen de-
pendence and inflammation related gene expression.
Conclusions
Our study contributes to a better understanding of the ef-
fect of inflammatory-related genes on PC cell growth and
the potential inhibitory effect of LSESr (Permixon) on
these pathways. In particular, using primary cultures from
human PC tissue, we showed that the inhibitory effect of
LSESr (Permixon) on cell growth could be in part associ-
ated to the down-regulation of inflammatory-related genes
and to the activation of NF-kB pathway in prostate tissue.Competing interests
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